text:
U.S. Senator Dodd bows out of presidential race
Chris Dodd's official portrait.
United States Senator Christopher Dodd left the Presidential race last night with his head "held high", thanking "the Dodd Squad" and his supporters for their efforts and passion.
Dodd ended the night with the sobering support of just one state delegate's support in the Iowa Democratic caucuses. That was still better than Mike Gravel or Dennis Kucinich, who each received no votes of support. However, neither Gravel or Kucinich conceded, only Dodd and Joe Biden, who won the votes of 23 state delegates, or 1% of the vote.
Dodd's campaign began last year, at the Old State House in Connecticut, the location "where the first written constitution guaranteeing the right to representative government was enacted".
Dodd admitted that he "always knew" that his campaign would "be an uphill battle against very tough odds." But he rationalized that only "when you try can you truly make a difference. And that, my friends, we did."
Selections from his speech
This evening Democrats sent a clear message that this party is united in our belief that our nation needs change to restore our security, our Middle Class and all that makes this country great.
Our campaign has been about results. And even though tonight we didn't get the result we all were hoping for, this experience has been one of the most rewarding in my life of public service.
It was 47 years ago this month that I was seated with my family on the East Front of the United States Capitol in the bright winter cold and heard President Kennedy ask all Americans to be a part of something larger than ourselves.
It was a moment every American took part in. A moment that changed us as individuals and as a country.
For a generation of us, that moment fueled a hunger to answer the call of our President.
A hunger to make a difference.
While we came up short in the race for caucus votes tonight, our campaign has more than kept pace in the race of ideas.
By raising ideas no other Presidential candidate has ever proposed, let there be no doubt that this campaign has set the standard.
When we began this race, every Democrat was for ending the war in Iraq - a war that has made us not more secure, but less so.
But it was only when we stood up and said this President wouldn't get another penny to fight that war that other candidates committed to doing what was necessary to actually end it.
When we began this race, every Democrat—every American—agreed that in America, we should never need a national crisis to bring the country together with national purpose.
But only when we proposed a universal national service plan to create the first generation in history that served our country did the national service debate begin in earnest - to create that renewed sense of community we all want.
And after 7 years of insecurity and watching this President have to go into hiding when he traveled abroad, we were all for stopping this President's assault on the Constitution.
But it was only when I stood up and you stood with me—it was only when tens of thousands of Americans stood together and said we would do whatever it took to stop this President from shredding the rule of law—that we actually did stop him.
And that fight goes on.
Dodd recalled advice from his father, imparted nearly forty years ago: "There's no other calling in life where you can do as much for as many people as you can through public service. Lawyers only have so many clients. Doctors only so many patients. But a well-intentioned public servant can make a difference in the lives of millions."
Biden commented "I am not going away. I'm returning to the Senate as the Chairman of the Senate Foreign Relations Committee and will continue to ensure that we protect the nation's security and show our country that Democrats know how to keep America safe, keep our commitment to our troops and restore our country's respect in the world."
"Huckabee, Obama win Iowa caucuses" — Wikinews, January 4, 2008
"US presidential candidate Dodd applauded by League of Conservation" — Wikinews, June 1, 2007
Mark Murray. "More oh-eight (D): Biden and Dodd out" — MSNBC, January 4, 2008
Chris Dodd. "Dodd's Concession Speech" — Hartford Courant, January 3, 2008
"Primaries and Caucuses Results: Iowa" — CNN, January 3, 2008
Retrieved from "https://en.wikinews.org/w/index.php?title=U.S._Senator_Dodd_bows_out_of_presidential_race&oldid=1508721"
Christopher Dodd
2008 United States presidential election
Democratic Party (United States)
Pages with pull-quotes


text:
BTS 2013: Redfern unveils new UK taxi service
By Rob Gill / 5 February 2013
Redfern Travel has introduced a new taxi booking service through its existing online booking tool.
The Bradford-based TMC has teamed up with taxi specialist Cabfind and technology firm Micros Travel to offer the new option to clients through its Trips tool.
The new service allows travellers to book taxis across the UK both from their homes to a station or airport and also to their meeting or event at the other end of the journey.
Mark Bowers, joint CEO of Redfern, said he believed the company was the first TMC to offer this kind of service in the UK.
"What we have created with Cabfind is essentially a GDS for taxis by pulling together different providers across the UK," said Bowers. "It's just for UK taxis although potentially it could be introduced overseas.
"It works from postcode to postcode and is designed as an end-to-end solution. We focused on the UK because we have the central government contract for employees who travel predominantly in the UK."
The new facility also searches for the best available train ticket and best value accommodation for the entire trip.
"The system not only saves them time and money, it can now help them better manage their taxi spend. The days of ringing five different cab companies, trying to police taxi use and collecting receipts are long gone."

redpajama_set_name: RedPajamaCommonCrawl


text:
Why Women Are Essential in COVID-19 Numerous Studies
Redefining Lupus Clinical Trials Amid COVID-19 and Beyond
Get yourself Up-To-Date on COVID-19 Clinical trials at www.clinicaltrials.gov
Coronavirus Cure: How UC Davis researchers are participating in clinical trials | COVID-19 in contex
'Robust immune responses' found in Covid-19 vaccine clinical trials point to 2021 release
COVID-19: Drug Therapies and Clinical Trials
FDA Clinical Trial Guidance During COVID-19
Clinical trial evaluating antiviral drug remdesivir for treatment of COVID-19 Dr. Catharine Paules
Ensuring the clinical trial process is accommodating for participants has always been the goal. However, COVID-19 has forced industry, research organizations, doctors, and patients to think twice about the process and its impact on high-risk populations including people with lupus who are immuno-compromised..
In light of COVID-19, important considerations regarding the conduct of patient care and clinical trials have emerged including:
1. What are the perceptions and attitudes of people with lupus regarding clinical trial participation in the COVID-19 norm?.
2. What are the key barriers to taking part in clinical trials?.
3. What innovative steps are being used by industry to get trials re-ignited and more patient-friendly?.
4. What role can people with lupus play in redefining clinical trials of the future?
Lupus Therapeutics, the clinical trial innovation division of the Lupus Research Alliance (LRA), invites you to hear from a diverse, expert panel about clinical trial innovation and why COVID-19 may be the spark needed to empower patients and drive clinical trial innovation..
Albert T. Roy, Executive Director, Lupus Therapeutics, LLC.
• Shanelle Gabriel Singer, HBO Def Poet, Lyricist, Advocate for Lupus Awareness.
• Molly McCabe – Co-Founder of the former Molly's Fund Fighting Lupus and Member, LRA Board of Directors.
• David R. Karp, MD, PhD Chief, Division of Rheumatic Diseases, UT Southwestern Medical Center, President-Elect, American College of Rheumatology.
• Craig Lipset Advisor and Founder, Clinical Innovation Partners.
• Ajay Nirula, MD, PhD Vice President, Immunology, Lilly Biotechnology & Research Laboratories.
• Shalabh Singhal, MD Development Program Lead, Immunology & Fibrosis, Bristol Myers Squibb.
Learn more: http://lupusresearch.org.
http://lupustrials.org..
Lupus affects millions worldwide, and there is no cure. Please help the Lupus Research Alliance to raise awareness and funds for lupus research..
http://Twitter.com/LupusResearch.
http://Facebook.com/LupusResearchAlliance.
http://Instagram.com/LupusResearchAlliance
Video taken from the channel: Lupus Research Alliance
Video taken from the channel: ICU REACH
Coronavirus Cure: How UC Davis researchers are participating in clinical trials | COVID-19 in context
Video taken from the channel: ABC10
Subscribe to our YouTube channel for free here:.
https://sc.mp/subscribe-youtube.
Coronavirus vaccine clinical trials under way around the world are showing promise with "robust immune responses" produced in humans, and those encouraging results are holding up despite mutations being found as the Covid-19 pandemic continues. But how soon can we realistically expect the shots to be proven safe and effective and made widely available? The South China Morning Post's Elaine Ly spoke with Dr Kylie Quinn, a Vice-Chancellor's Research Fellow in the Translational Immunology and Nanotechnology Programme at RMIT in Melbourne, Australia. The award-winning scientist also coordinates the Women's Initiative Programme at the Australia and New Zealand Society of Immunology..
Website: https://scmp.com.
Facebook: https://facebook.com/scmp.
Twitter: https://twitter.com/scmpnews.
Instagram: https://instagram.com/scmpnews.
Linkedin: https://www.linkedin.com/company/south-china-morning-post/
Video taken from the channel: South China Morning Post
NYU Langone's Dr. Marc K. Siegel and Dr. Mark B. Pochapin discuss the current state of drug testing in the treatment of COVID-19.
Video taken from the channel: NYU Langone Health
View the webinar playback featuring ARM and FDA representatives Tejashri Purohit-Sheth and Ilan Irony from the Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, as they discuss the effect of COVID-19 (coronavirus) on cell and gene therapy clinical trials. Discussion topics include assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
Video taken from the channel: Alliance for Regenerative Medicine
Penn State Health Milton S. Hershey Medical Center has begun enrolling participants in an international clinical trial evaluating an investigational antiviral drug, remdesivir, for treatment of coronavirus disease 2019 (COVID-19).
Video taken from the channel: Penn State Health
Why it's critical that women join the COVID-19 trials "Lack of enough women, particularly minority women, participating in clinical trials can skew research data towards men," Mallampalli said. "Essentially, not being able to analyze data by sex, age and race/ethnicity will not ensure adequate treatment for a given population, and this can lead. "There is currently no standard of care for anticoagulation in hospitalized COVID-19 patients, and there is a desperate need for clinical evidence to guide practice," said NIH Director Francis S. Collins, M.D., Ph.D. "Conducting trials using multiple existing networks of research sites provides the scale and speed that will get us answers. 2 days ago · Oxford and AstraZeneca resume COVID-19 vaccine trial the university confirmed the restart across all of its U.K. clinical trial sites after regulators gave the go-ahead following the pause on. This is needed to catch more rare side effects. Many clinical trials have a data and safety monitoring board This has shifted with COVID-19 trials.
Leaders of the Latino community, hit hard by the coronavirus pandemic, roll up their sleeves for vaccine trials. Volunteers point to startling inequities exposed by COVID-19. Some potential COVID-19 vaccines are already in the third stage of clinical trials. It's taken a lot of effort and money to squeeze a process that can normally take five years into about 10.
Running a large clinical trial is complex and finding the right mix of volunteers is often challenging and can take months, but Hiatt thinks the COVID-19 trials will be different. "The altruistic. Early-stage clinical trials show that three COVID-19 vaccines are generally safe and induce an immune response in healthy people. The results of two of these studies were published online. Per the New York Times' Covid-19 vaccine tracker, 3 out of the 9 companies in late stage trials have declared an annual capacity totaling to about 3.5 billion doses.
The second is a regulatory issue. One principle is that the manufactured and sold product has to be "identical" in key aspects to the product used during clinical trials. AstraZeneca paused its COVID-19 vaccine trials after a volunteer developed a potentially serious side effect.
Why that's actually good news.
Is Because of the long duration of preinvasive detectable disease in women of reproductive age, annual screening in the absence of specific risk factors is unnecessary for most women.
from Primary Care Medicine: Office Evaluation and Management of the Adult Patient
by Allan H. Goroll, Albert G. Mulley
Wolters Kluwer Health/Lippincott Williams & Wilkins, 2009
These trials have significantly increased the overall number of women in clinical trials.
from Sex Differences in Cardiovascular Physiology and Pathophysiology
by Babbette LaMarca, Ph.D., Barbara T. Alexander, PhD, FAHA, FAPS
Elsevier Science, 2019
Because these women are at increased risk for adverse events, further diagnostic evaluation, as well as interventions to modify risk factors, relieve symptoms, and improve microvascular and macrovascular function, should be considered.
from Mayo Clinic Internal Medicine Board Review
by Amit K. Ghosh
OUP USA, 2010
Because LMWHs are not routinely monitored the possibility that women could be at risk for higher anti-Xa levels and subsequently at greater risk for bleeding when these agents are used may occur.
from Principles of Gender-specific Medicine
by Marianne J. Legato, John P. Bilezikian
Elsevier Academic Press, 2004
Because most infections in males and females are asymptomatic, screening atrisk individuals is a cornerstone of secondary prevention.
from Conn's Current Therapy 2020, E-Book
by Rick D. Kellerman, KUSM-W Medical Practice Association, David Rakel
Because this is a modifiable risk factor, education of women about the dangers of hypertension and intensive screening becomes important.
from Netter's Cardiology E-Book
by George Stouffer, Marschall S. Runge, et. al.
Large-scale clinical trials of new treatment options for cardiovascular conditions need to enroll women, and the results of such studies need to be analyzed by sex in order to inform individualized care that will lead to improved outcomes.
from Sex-Specific Analysis of Cardiovascular Function
by Peter L. M. Kerkhof, Virginia M. Miller
In this case, because of test sensitivity of 84% for MammaPrint versus 98% for NIH criteria, some women who will progress will be categorized as low risk and not recommended for chemotherapy.
from Genomic and Personalized Medicine: V1-2
by Geoffrey S. Ginsburg, Huntington F Willard
They make no recommendation for or against screening asymptomatic, low-risk women and found insufficient evidence to recommend for or against routine screening of men.
from Textbook of Family Medicine E-Book
by Robert E. Rakel
Because women often experience greaterdisability after MI, it isimperative that future research efforts includewomeninsufficient numbersto examine gender differences in symptom presentation, risk factors, and treatment options.
from Handbook of Psychology, Health Psychology
by Irving B. Weiner, Arthur M. Nezu, et. al.
Wiley, 2012
5 Questions Regarding Numerous Studies
Numerous Studies The Way You Will Benefit and What You Need To Ask
Volunteer for Numerous Studies
Who Funds Numerous Studies
Take Early Numerous Studies Having a Touch of suspicion
Feb Is really a Here we are at Celebrating Black History, Heart Health … and Numerous Studies
Flying having a Newborn
Safeguard The Skin Throughout the Summer time
Mobile Phone Use May Disrupt the Fetus
Goltimuro says:
I'm not a Dr just curious. Has there been any attempt on covid 19 patients to use surfactant to try to open the lungs up or use of hyperbaric chambers with hi pressure o2
Shalilbine says:
Coronavirus Studies
There are 202 clinical studies on Coronavirus (CV) listed on the site clinicaltrials.gov. A few of these are observational studies, some are studies on an offbeat treatment and are available at only one or two institutions, most are for the treatment of the critically ill, and the majority are being done in countries outside the United State. I will admit, upon looking at the study offerings, I am disappointed in what little is being done in the United States. Of that 202 studies there are only a dozen or so treatment studies here in the United States.
At this time, almost all for the studies are for patients who are critically ill, at a time when it I probably too late for antiviral to help much. (But I hope that I am wrong). In the setting of critical illness, the potent anti-inflammatories such as the IL-6 inhibitors still make sense.
What we needs are studies offered to CV patients before they are so ill that they are in the intensive care unit. Actually, we needs studies on CV patients who have just been diagnosed with the disease. It is in this setting where antiviral treatment should do the most good. It is also in this setting where a lot of people will not advance to critical illness.
We need studies to offered at 100 or more medical centers, not just 20 or 30.
We need large studies that randomize patients to one of many possible combinations of treatment. There is only one place in the world where just a study is offered, at that is in Bangkok, Thailand
The approach researchers are taking is painstakingly slow. This might be fine for testing new treatments for colon cancer but it is grossly inadequate for this epidemic. The FDA and researchers are thinking "we will have some information on several drug treatments in 5 or 6 weeks, then we will start another study, combining promising treatments and that will take another 5 or 6 weeks. It will probably be around July or August when we will optimize treatment.
In other words, less than one tenth of one percent of CV patients area being put on study.
This is totally inadequate.
In my opinion, we need multi-armed studies, aimed at enrolling 1,000 patients a week, and testing treatments early in the disease processes.
Here is a study that I suggest. Have a seven armed study for early diagnosed patients. People are randomized to get a) no treatment, b) Remdesivir, c) Favipiravir, d) a combination of Remdesivir and Favipiravir, e) Hydroxychlroroquine plus Remdesivir, f) Hydroxychloroquine plus Favirpiravir, g) Hydroxycholoroquine plus Remdesivir plus Favipiravir.
You could have the same study offered to hospitalized patients who are not yet critically ill.
You could have the same 7-arm study, but replace Favipiravir with EIDD-2801 (another oral anti-viral RNA polymerase inhibitor.
And offer this one to both early diagnosed patients and those that need hospitalization.
Or you could offer the same 7-arm study but instead of giving oral Hydroxychloroquine offer the anti IL-6 antibody Tocilizumab (Actemra) which is a shot in the arm given once a week for two weeks.
Or the anti IL-6 antibody Sarilumab (Kevzara)
Or the anti IL-6 antibody Siltuximab (Sylvant).
Keep in mind, Actemra, Kezara and Sylvant are drugs that are FDA approved to arthritic conditions. These drugs should be readily available with an ample supply
And, of course, there will be other potential drugs, coming in short order.
There is a challenge, of course, in offering studies to those newly diagnosed. If you included a lot of young and healthy in these early case studies, you might find that almost everyone does well and you might now be able to detect an improvement in survival (although you might be able to see the virus clear faster). You could restrict enrollment to individuals over age 35 or individuals who have diabetes or other chronic conditions. Furthermore, you would be recruiting people who would ordinarily be staying at home in isolation. Getting them to come in to the office for an intravenous infusion (for those getting Remdesivir) might be difficult (but this can be accomplished). A special infusion center would have to set up and staffed by brave nurses who are willing to gown up and risk the disease. This would be a ideal setting for nurses who have caught and recovered from CV, for they should have ample antibodies to prevent re-infeciton.
For any of these seven-armed studies you would need to recruit probably 100 subjects per arm. Those who get on Placebo and progressively get worse, may then be offered a new study. In fact, anyone who progresses regardless of what treatment they have been given may be offered another study, if that study is not a repeat of what they have just failed. You might end up needing 200 individuals per treatment arm, if you want good confirmation of which treatment or combination is the best.
To run all of these studies you need a great deal of cooperation. You need to have physician groups or hospitals experienced with performing clinical studies. But they are out there. There certainly is more than 100 groups who could participate in enrolling and treating study patients. (probably more like 500). You need training. You need a protocol. You need reliable shipment and containment of drug. These medical groups are accustomed to this. Conducting studies is not rocket science
The FDA needs to act on this now. Come out of the stone age of research. We hare in an international emergency and they have to act like it is an emergency. The United States was slow on the draw in getting people isolated and now we have well over 100,000 with CV. In another week it may be 200,000 to 300,000 and our health system is overloaded. Look, there is no shortage of individuals who can and are willing to participate in clinical studies Why is the FDA slow on the draw here?
There needs to be very large studies, with rapid enrollment, done at over 100 institutions, both inpatient and outpatient with multi-armed studies comparing combination treatment.
Hydroxychloroquine should be available, since there are three manufacturers, increasing production.
Gilead should be making Remdesivir in large quantities and I would think would soon have 10,000 doses. (not an easy drug to make)
Favipiravir is made in Japan, but they should have a lot of it. Favipiravir is a simple chemical compound and should be easy to manufacture.
EIDD-2801, made by Ridgeway Pharmaceuticals may not be entirely ready yet. The drug may not be well characterized as to absorption and side effect profile. I am less sure about this one.
Meztibar says:
They're WASTING THEIR TIME!!! A Covid-19 VACCINE was developed at the same time that BILL GATES financed the development of the TWEAKED CORONA VIRUS from where COVID-19 was created in a USA Lab and then transported to the Lab in Wuhan for those Immunologists to MASS PRODUCE!!! Bill Gates has a PATENT on COVID-19 VACCINE and all CORONA related stuff too!!!
WAKE UP ALLLLLLLLLL OF YOU DEVELOPING VACCINES, because they won't contain the lethal components that BILL's does and IS THE ONE THAT WILLLLLLLL BE USED!!!
Yes! Sorry guys, but you are wasting your time and a LOT of money which could be spent on other WORTHY research and immunological developments! You're farting against thunder and DREAMING!!!
BTW… Dr Rashid Buttar has copies of those CORONA and COVID-19 patents owned by Bill Gates… fortunately before all proof of their existence was WIPED OFF THE NET! ������ The ONLY 2 trustworthy TRUTHERS in my opinion, are Dr Rashid BUTTAR on his own channel and website, and DEL BIGTREE on �� The Highwire Channel.
I also take direction from my MOST TRUSTED Heavenly mentor, Matthew Ward, who has NEVER ONCE been incorrect since I first encountered his existence in 2004.
�� https://www.matthewbooks.com/july-2-2020/
Do read previous FREE monthly messages pertaining to this LAB CREATED VIRUS intended to CULL BILLIONS… YES! You read that correctly… BILLIONS!
�� South Africa ����������
Deladi says:
https://www.globenewswire.com/news-release/2020/07/07/2058547/0/en/In-Vitro-Testing-of-Innovation-Pharmaceuticals-Brilacidin-for-COVID-19-Shows-Consistent-Anti-SARS-CoV-2-Efficacy-Manufacturing-Preparation-Underway-for-COVID-19-Clinical-Trial.html
Kalar says:
We are looking for #PIs for #compassionate use or #emergency trial for #COVID-19 with severe #ARDS patients with our #Olinvacimab + standard of care +/low dose #dexamethasone.
Olinvacimab is anti-VEGFR2 neutralizing human IgG with clear safety profile. https://www.medrxiv.org/content/10.1101/2020.07.26.20159756v1.full.pdf?fbclid=IwAR3Pv566LQ8IyIe5yQ_l-o-Go1gFa4_mS44zHH3u60JjXG67J4sBq4MeIRw
Turisar says:
I've seen The Fantastic Fungi and it suggested that our defenses for pandemic viruses could be found in these mushrooms and other fungi. We really need to take care of our forests and environment, and I hope governments across the globe start thinking and enforce more stringent measures in protecting our only home.
https://aapsonline.org/coronavirus-victims-die-while-government-hoards-medication/ This is written by the National Board of Drs. and Surgeons, It is not partisan and look at what they say! Many state governments are hoarding more than 100 million doses of hydroxychloroquine (HCQ) while victims of COVID-19 are dying from lack of early treatment, which an increasing number of physicians and scientists believe is crucial to save lives! Reports to date of results in more than 2,300 persons who received HCQ show that more than 90 percent experienced clinical improvement or did not become ill. HCQ is also being used successfully as a prophylaxis in other countries, including India, to protect medical workers, first responders, household contacts, and other persons at risk of exposure. The COVID-19 mortality rate in India is only one per million in population, compared with more than 200 per million in the U.S.! But in the USA the politics have halted treatment of COVID patients because these state politicians are stopping DRS from prescribing HCQ and locking it away in govt warehouses to Rot! This because Pres Trump pushed for it! https://justthenews.com/politics-policy/coronavirus/pa-forced-nursing-homes-take-covid-patients-health-secretarys-mother These same left Governors and their people have made nursing homes accept COVID patients and the result is more than half of all deaths in nearly every state is in Nursing Homes! In NYC it was just exposed 5200 died in Nursing homes. Pennsylvania made nursing homes accept COVID patients, but the Penn State Health Secratary's Mom was moved out and into a Hotel! That tells me they Knew it would be deadly and it was!
Sairis says:
Its could have this side effect it could have that side effect blah blah blah.
IN THE MEAN TIME Dr Seigels NINETY SIX YEAR OLD father took it and was better the next day.
PS I know of a couple of guys who took this drug in Vietnam for malaria protection FOR Months at a Time With NO Side effects
Coronavirus Deaths and Individuals of George Floyd and Ahmaud Arbery Have Something in keeping Racism
Selecting the Sex of the Baby Details Myths
In The Event You Give Kids Benadryl When Flying and Traveling
A Breech Baby Can Alter The Way You Deliver
Rethinking In Which You Look for Food


text:
import { EMBER_FRAMEWORK_OBJECT_OWNER_ARGUMENT } from '@ember/canary-features';
import { FrameworkObject, setFrameworkClass } from '@ember/-internals/runtime';
import { inject as metalInject } from '@ember/-internals/metal';

/**
 @module @ember/service
 @public
 */

/**
  Creates a property that lazily looks up a service in the container. There are
  no restrictions as to what objects a service can be injected into.

  Example:

  ```app/routes/application.js
  import Route from '@ember/routing/route';
  import { inject as service } from '@ember/service';

  export default class ApplicationRoute extends Route {
    @service('auth') authManager;

    model() {
      return this.authManager.findCurrentUser();
    }
  }
  ```

  Classic Class Example:

  ```app/routes/application.js
  import Route from '@ember/routing/route';
  import { inject as service } from '@ember/service';

  export default Route.extend({
    authManager: service('auth'),

    model() {
      return this.get('authManager').findCurrentUser();
    }
  });
  ```

  This example will create an `authManager` property on the application route
  that looks up the `auth` service in the container, making it easily accessible
  in the `model` hook.

  @method inject
  @static
  @since 1.10.0
  @for @ember/service
  @param {String} name (optional) name of the service to inject, defaults to
         the property's name
  @return {ComputedDecorator} injection decorator instance
  @public
*/
export function inject() {
  return metalInject('service', ...arguments);
}

/**
  @class Service
  @extends EmberObject
  @since 1.10.0
  @public
*/
const Service = FrameworkObject.extend();

Service.reopenClass({
  isServiceFactory: true,
});

if (EMBER_FRAMEWORK_OBJECT_OWNER_ARGUMENT) {
  setFrameworkClass(Service);
}

export default Service;

redpajama_set_name: RedPajamaGithub


text:
Marine assigned to Trump's helicopter squadron tests positive for Covid-19
A Marine assigned to the military helicopter squadron responsible for transporting the president has tested positive for Covid-19, a Marine Corps spokesperson told POLITICO.
Marine One departs the White House. | Samuel Corum/Getty Images
By Lara Seligman, Daniel Lippman and Marc Caputo
The Marine, assigned to Marine Helicopter Squadron 1, was tested on Tuesday and received the positive result on Thursday, said spokesperson Capt. Joseph Butterfield, adding that the squadron administers 80 to 100 tests per week.
The squadron was informed of the positive test on Thursday, ahead of the president's planned travel to Bedminster, N.J., this weekend, Butterfield said.
The squadron is sanitizing all aircraft in the squadron and beginning the process of contact tracing.
President Donald Trump and Melania Trump have tested positive for Covid-19.
Confirmed U.S. Cases: 7,292,422 | U.S. Deaths: 208,068
How coronavirus will change the world permanently
Coronavirus cases, tracked state by state
Are you a health care worker? Tell us what you're seeing
TOP DEVELOPMENTS
Here's what we know — and don't — about Trump's Covid case.
Joe Biden tested negative for Covid-19.
Trump's diagnosis could spell disaster for his campaign.
The Trump team is on guard against foreign adversaries who could exploit the president's illness.
Read all coronavirus coverage »
"Out of an abundance of caution, Marines who may have had contact with the infected Marine have been removed from the detachment," Butterfield said, noting that the infected Marine was never in direct contact with the president's helicopters, which are referred to as "Marine One" when he is aboard. "No impact is expected to the President during his trip to Bedminster, N.J."
A White House official confirmed that the Marine "had no contact with the president or any administration personnel."
This marks the latest instance of coronavirus hitting close to the president. This week, the cafeteria and another eatery at the Eisenhower Executive Office Building were closed after a cafeteria employee tested positive for the virus. In May, a personal valet for President Donald Trump and a senior member of Vice President Mike Pence's staff tested positive.
More recently, the girlfriend of Donald Trump Jr., Kimberly Guilfoyle, received a positive test result for coronavirus, leading her and Don Jr. to have to leave early from Trump's Mount Rushmore speech during the July 4 holiday weekend.
As of 2017, the presidential helicopter squadron, also called HMX-1 and based at Quantico, Va., had 23 primary aircraft, including 11 Sikorsky Sea Kings, eight White Hawks and other helicopters, according to Bloomberg Businessweek.
The Defense Department has reported 32,728 cases of Covid as of Wednesday, including 22,769 among members of the military. Overall, 51 department personnel have died, including three service members. The Marine Corps has 2,600 cases.
White House,
Marines,
Donald Trump 2020,
Marine One,


Consider this a warning: It's possible I will be featured on the cringe-worthy "People of Walmart" website in the near future.
No, I wasn't strutting around the produce section in a tutu or a French bikini. I only do that in the home and gardening section.
My potentially embarrassing outfit at America's favorite corner mom and pop megastore happened because of a physics equation.
I'm just going to caption this as a splitting image of my success.
You can call it The Split Pants Formula.
After dropping my Africa-bound wife and two oldest kids off at the airport on Thursday morning, I was supposed to go into work quickly and then take my car for a service appointment.
The loud RIIIIIIP sound coming from my nether regions forced me to change plans. I was too far away from home to change pants, so I headed to the nearest Walmart for a shopping spree. I'm sure I was a sight to behold, walking with my legs tightly pressed together while pushing a cart to shield my ripped pants from plain view. Fortunately, the jeans tore low enough so as to not expose my whitey-tighties to the world. Sorry, creepers.
This is not my first experience with ripped pants.
There's a scene in Forrest Gump when everybody's favorite purveyor of boxed-chocolate philosophy dramatically lifts himself up from a rocking chair, slowly walks off his front porch and takes off sprinting.
First, he ran to the end of his road. Next, he high-tailed it through his small town of Greensbow, Alabama, and continued through his county and across his state. From there, Gump headed to the Pacific Coast. He then left a Santa Monica pier and kept running in the other direction until he arrived at a lighthouse on the Atlantic Ocean shore.
"Yeah," Forrest responded, matter of factly.
As the story goes, Gump kept on running and running and running for years, criss-crossing America in an epic adventure, eventually gaining followers, inspiring people — "It happens" and "Have a nice day!" 🙂 — and attracting the curiosity of media members.
"I just felt like running," he told reporters.
In March, I scheduled a doctor's appointment. I was at my all-time-high weight. I felt miserable in so many ways. I feared that my eating habits and lack of exercise had caused me to get type II diabetes. I was a mess.
Fortunately, my blood sugar was at a decent level.
My blood pressure was a tad high, but not terrible.
My swollen legs had edema, so my doctor prescribed me a diuretic.
Me at The Cheesecake Factory? What the? Don't worry. I resisted everything normal people eat there and settled for a much healthier salad. I wasn't even tempted to order cheesecake. No, really!
Did you read that shocking and depressing New York Times article that came out earlier this week?
And, no, I'm not talking about the presidential campaign.
I'm referring to the article that sent tremors through the weight-loss world. The one in which it was revealed that the vast majority of the 16 contestants from Season 8 of The Biggest Loser reality show have gained back most if not all of their weight.
While that's a bummer for them, the worst part about the article was how it focused on the concept that the bodies of overweight people do a pretty effective search-and-rescue mission for lost pounds. Their metabolisms apparently slow down to the pace of an 80-year-old grandpa driving in the fast lane, too.
There is more dreary info about our body's so-called "set point" and the hunger-controlling hormone leptin, but I'm going to spare you the disheartening details.
Challenge results: I'm changing for good!
On April Fool's Day, I began a month-long weight-loss fundraiser called "Jody's Changing For Good Challenge." I'd already decided to start a new weight-loss/health program, so I figured it would be fun to try to earn some money to help my wife and two oldest kids for their upcoming humanitarian trip to Kenya, Africa.
I love the multifaceted changing-for-good concept.
I've been obese my entire adult life. It's time to change that for good.
If I can do some good and assist a worthy cause while improving my health and shedding pounds, how awesome is that?
Another bonus: I love that others have been sparked to make positive changes in their eating and exercising habits because I've been living my life out loud.
This has been a special month for me.


SI-UK is hosting an exclusive, most illustrious SI-UK University Education Fair at Lucknow in January/February 2019.
Hosted by SI-UK, a global agency, with 16 offices in nine countries, inclusive of two in the UK. Our expert team of UK Education specialists mentor you to make the right choices. Participating Universities make spot offers and provide scholarships to the qualifying students.


text:
How a Wall Street Fugitive Inspires the World of Wine and the Wine Country Lifestyle
The future of Douro reds – Old World blends vs. New World varietals
Annette Hanami January 26, 2012 Douro Valley, Perspectives, Portugal
The Douro Valley
The production of high quality Douro reds is a relatively young endeavor, given impetus when the law requiring Ports to be aged downriver in coastal Vila Nova de Gaia – an expense favoring the larger shippers – was lifted in 1986. This broke down some of the financial barriers for smaller growers and investors to make their own wine in the Douro Valley, and it favored dry wines over Port. As Christian Seeley of Quinta da Romaneira explained, the lead time to become a new Port brand is long because of minimum aging requirements and the fact that buyers require the full range of Port styles including age-dated Ports. In the meantime, producing dry wines was less capital- and time-intensive.
But as Douro wine producers develop export markets for their new brands, what wines will appeal to novice consumers in the major markets of the U.S. and Asia that lean towards single varietal wines? Douro wines are traditionally blends of mostly native grape varieties but more single varietal wines such as Touriga Nacional are getting accolades, most recently Quinta do Vallado's #7 ranking on Wine Spectator's Top 100 wines of 2011. But are they better and are they the future of Douro wines?
Historically, dry Douro reds – and the Port wines often made from the same vineyards – are made from grapes that are mixed planted and co-fermented. This practice has its origins in growers wishing to reduce their risks to specific grapes not ripening well in any given year, particularly in light of the Douro's monoculture of vine growing and high labor costs. Today, modern vintners plant vineyards in single varietal blocks and more often than not, create a blended wine from them.
There are about 60 red grape varieties authorized, of which five are the most important. The 'noble' grapes are Touriga Nacional for power and structure, Touriga Franca (formerly known as Touriga Francesa) for aromatics, Tinta Roriz (a clone of Tempranillo) for berry fruit and spice, Tinta Barroca for body and Tinto Cao for deep color and acidity.
From a marketing perspective, says Rui Cunha of Secret Spot, it makes all the sense in the world to make single varietal wines, especially for the most noble grape, Touriga Nacional which is indigenous to Portugal and grows well throughout Portugal wine regions Douro, Dao and Alentejo. But it has very low yields, about 25 hl/ha compared to 45 hl/ha for Tinta Roriz (clone of Tempranillo) and has problems flowering. Because of this, Touriga Nacional was almost extinct until the mid-20th century when Quinta do Noval revived it, and it still constitutes just a small percent of total Douro acreage. It's a small-berried, thick-skinned grape that can give too much power to a wine by itself depending on where it's grown. For Symington Family Estates' majestic Quinta do Vesuvio in the remote Upper Douro, Touriga Nacional's power is softened by the addition of Touriga Franca.
Touriga Nacional and Touriga Franca are also valued at SFE's Quinta de Roriz, where both are prioritized for the dry wine program, says Co-Director Rupert Symington while Tinta Barroca and Tinto Roriz are designated for Port. At Quinta do Vale D. Maria, Cristiano van Zeller believes that Touriga Franca, with its lifted aromas, is more of a signature grape than Touriga Nacional.
Nevertheless say van Zeller, "there is no such thing as one single grape making great wine with the exception of Burgundy." And he has every reason to advocate single varietal wines, especially Tinta Roriz as Tempranillo. According to Van Zeller, his 3rd grandfather introduced Tempranillo to Portugal from Aragon in Spain, planting it at the namesake Quinta de Roriz in the Douro. Coming from Aragon, it is the reason he says, that the grape Tinta Roriz is called Aragonez in Alentejo to the south.
But Tinta Roriz doesn't grow the same way in the Douro as the Tempranillo clone does along the same river in Toro and Ribera del Duero on the Spanish Meseta. As a winemaker of Toro also, van Zeller says the soils and climate are completely different. He compares Ribera del Duero's purely continental climate and clay, limestone soils with the Douro's Mediterranean and Continental influences with schist soils. "Tannins are too soft here, and the grape too vigorous." He says one would need to get below one hectoliter per hectare to get good expression. According to van Zeller, in 25 years, there have been only three good years for Tinta Roriz. However, it is a consistent performer with good yields and spicy character, making it an important blending grape.
Van Zeller said that for future plantings, he will return to field blends for complexity and that any difference in ripening times will add to freshness in the blend. He has also found that when certain grapes are co-planted, like Touriga Nacional and Touriga Franca, that they ripen simultaneously.
Another producer who also has an interest in single varietal wines, Tomas Roquette at Quinta do Crasto, said that they produce single-varietal Touriga Nacional and Tinto Roriz wines for their consumers but in his opinion, the best wines are still blends. More specifically he says, old-vine, field blends, such as the Quinta do Crasto Reserva, show "the beauty of the 25/30 different varieties mixed and the final result is a full complex wine." According to Roquette, while single varietals can make great wines, he believes the best wines – which he defines as "most complete" – are the field blends.
Quinta do Vale Meão explores the potential for individual grape varieties for example by planting Touriga Nacional on separate schist, granite and aluvion parcels on their estate. Winemaker Luisa Olazabal then vinifies each of these plots and other grape varieties on their own, saying that it allows them "to get a sense – which is becoming more and more accurate – about the potential of each one." But for her, the objective is not to make single-varietal wines, but to explore "to the utmost, the combination of the different traditional Douro varietals … and uphold the originality and complexity of our wines." Their highly-regarded Quinta do Vale Meão Douro wine (2008 vintage, ranked # 32 Wine Enthusiast Cellar Selection 2011) is a blend, with Touriga Nacional being the backbone of all their wines.
In my tastings throughout the Douro, I have to agree that the best wines were blends (with a few exceptions), although I don't think single-varietal plantings and wines have had enough history to show their true potential since there are so many microclimates in the Douro in which to experiment, even for grapes like Tinta Roriz. Olazabal believes Tinta Roriz' inconsistencies are due to the grape's sensitivity to "the huge diversity of solar expositions and vigor due to the geography of the region" and they work to minimize them.
For me, the Douro reds are like Bordeaux, a blend of primarily five grape varieties with three being most important, in Douro's case, Touriga Nacional, Touriga Franca and Tinta Roriz. The difference though, is that in Bordeaux, climate necessitates blends including cabernet sauvignon, whereas in Douro, the warm climate can certainly ripen Touriga Nacional well enough to stand on its own. With more experimentation and new clonal materials, as well as consumer demand, the future looks bright for signature varietals like Touriga Nacional, but it will never replace the typicite of the blends.
Below are a few of my favorites from a recent trip (in no particular order):
Quinta de S. Jose Douro Reserva 2009 – Touriga Nacional, Touriga Franca, Tinta Roriz
Quinta de S. Jose Douro Gran Reserva 2009 – about half Touriga Nacional
Quinta do Infantado Douro (organically farmed) 2008 – Touriga Nacional, Tinto Roriz, Touriga Franca
Quinta do Infantado Douro 2009 – Touriga Nacional, Tinto Roriz, Touriga Franca
Altano (Symington) Douro 2009 – Touriga Franca, Tinta Roriz, Tinta Barroca
Chryseia (Pratts & Symington) Douro 2009 – about 50/50 Touriga Nacional, Touriga Franca
Quinta da Gricha Douro Touriga Nacional 2008
Quinta da Gricha Douro Gran Reserva 2007 – field blend of old vines including Touriga Nacional, Touriga Franca, Tinta Roriz, Tiinta Francisca and Tinto Cao
Quinta da Avigados Douro Gran Reserva 2008 – Touriga Nacional, Tinto Roriz, Touriga Franca
Ramos Pinto Douro "Duas Quintas" Reserva 2008 – Touriga Nacional, Touriga Franca, Tinta Barroca
Casa de Casal de Loivos (Van Zeller) Douro 2009 – single vineyard, field blend
Quinta do Vale d. Maria Douro 2009 – traditional blend
Quinta do Vale Meão Douro 2009 – Touriga Nacional 57%, Touriga Franca 35%, Tinta Barroca 5%, Tinto Roriz 3%
Quinta do Crasto Douro Reserva 2009 – field blend of 25-30 grapes, old vines
Quinta do Vallado Douro Touriga Nacional 2009
Cristiano van Zeller Douro red wines Douro tinto Douro wines Luisa Olabazal Quinta do Crasto Quinta do Vale Meao Quinta do Vallado Quinta Vale d. Maria red wines Tomas Roquette viniportugal wines of portugal
wine_muse
When our in-person Bourgogne wines events were de
#TBT. I had the most delightful discovery this wee
Wine country can mean different things to so many
Loved this beef chili at Farmstead restaurant, per
Lots of really diverse, interactive, outdoors and
Yes we're doing the touristy things and we're havi
You know that tasting room at the intersection of
The latest in new, super modern wineries arriving
In pursuit of quality, Hess Collection uses an opt
In my latest agenda, I feature a couple of great u
Categories Select Category Beaujolais (1) Food & Wine (80) Food (20) Sake (1) Perspectives (44) aMuse bouche (9) Books (5) Uncategorized (1) Wine Business (29) Wine Regions (252) Argentina (2) Mendoza (1) Salta (1) Asia (6) China (1) Hong Kong (3) Australia (7) Hunter Valley (1) Melbourne (3) Mornington Peninsula (1) South Australia (2) McLaren Vale (1) Tasmania (1) Victoria (3) Heathcote (1) Strathbogie Ranges (1) Yarra Valley (2) Chile (7) Casablanca (1) Colchagua (2) Maipo Valley (2) France (60) Alsace (1) Bordeaux (19) Cotes de Bordeaux (1) Unions des Grands Crus de Bordeaux (1) Burgundy (13) Beaujolais (1) Chablis (3) Cote Chalonnaise (1) Champagne (3) Languedoc (3) Corbieres (1) Cremant de Limoux (1) Minervois (1) Paris (1) Provence (5) Rhone Valley (11) Northern Rhone (4) Southern Rhone (5) Gigondas (2) Roussillon (1) Southwest France (2) Sud de France (2) Germany (11) Mosel (2) Pfalz (5) Rheingau (2) Greece (1) Santorini (1) Israel (2) Italy (13) Alto Adige (1) Friuli Venezia Giulia (2) Collio (2) Rome (1) Trentino Alto Adige (2) Veneto (6) Soave (2) Valpolicella (1) New Zealand (1) Portugal (14) Douro Valley (9) Madeira (3) Porto (8) Slovenia (1) Stajerska (1) Spain (11) Bierzo (1) Jerez (2) Rias Baixas (3) Ribera del Duero (2) Rioja (3) Switzerland (1) U.S. (124) Bay Area (5) Bodega Bay (1) California (1) Los Angeles (1) Mendocino (6) Anderson Valley (4) Napa Valley (102) Calistoga (7) Carneros (7) Coombsville (3) Downtown Napa (17) Howell Mountain (2) Mount Veeder (2) Rutherford (5) Saint Helena (12) Spring Mountain (1) Stags Leap (4) Yountville (3) New York (1) Oregon (2) Willamette Valley (1) Dundee Hills (1) San Francisco (1) Sonoma (6) Sonoma Coast (2) Virginia (1) Monticello (1)
Archives Select Month January 2019 August 2018 March 2018 February 2018 June 2017 February 2017 September 2016 July 2016 January 2016 August 2015 July 2015 May 2015 April 2015 February 2015 January 2015 November 2014 September 2014 August 2014 July 2014 June 2014 May 2014 April 2014 March 2014 February 2014 November 2013 October 2013 September 2013 August 2013 July 2013 June 2013 May 2013 April 2013 March 2013 February 2013 January 2013 November 2012 October 2012 September 2012 August 2012 May 2012 April 2012 February 2012 January 2012 December 2011 November 2011 October 2011 September 2011 August 2011 July 2011 June 2011 May 2011 February 2011 January 2011 December 2010 November 2010 October 2010 August 2010 July 2010 June 2010 May 2010 April 2010 March 2010 February 2010 January 2010 December 2009 November 2009 October 2009 September 2009 August 2009 July 2009
Judgment of Grgich
Dive Into Downtown Napa's Global Street Food Scene
The Wines of Provence: Fifty Shades of Rosé
Hall Wines in Napa Valley: Art That Makes You Smile
Escape to Chile In Your Own Back Yard
Mount Veeder Appellation – Napa Valley Mountain Wines With a Twist
Building life's bridges through wine – Project Zin
How Top San Francisco Chefs Are Liberating the Way We Eat and Drink
Stags Leap District: A Legend in Its Own Time
The Man Behind the Brand: What You Don't Know About Georges Duboeuf
California Home+Design in Wine Country
Downtown Napa tourism
Napa Valley Tourism
The Real Argentina
© 2021 Annette Hanami, Wine Muse
Powered by One Designs


text:
RomanticLoveBooks.com
Chapter 1627: Transaction With The Yellow Cloth Girl
After a good while, the girl said slowly: "Don't you want to fight to the end? Kill your way above the nine heavens and sweep through the emperors and gods? If you want to be the last man laughing, you need to have all the untouched treasures in this world or you won't be able to go further."
"You're wrong about that." Li Qiye smiled and said: "No point in having an abundance of resources. Even if you have more, at the end of the world, it will only lend you a bit of strength. The truth is that you can only rely on yourself in order to win. Personal strength is the greatest force at the end of the world." He solemnly said.
"But you still need resources along the way?" The girl said: "How can your men contend against them without ample resources? How can you train your own legions? Why would people join your banner? I don't need to explain these logics to someone who had lived for so long."
She paused for a moment before continuing: "I can help you in this regards, giving you some things unavailable to others."
"If you know how long I have lived for, why do you think I don't have enough resources? Plus, it's not like I haven't been there before, I'm even more familiar to each blade of grass up there than you." He smiled in response: "If you think you can give me some rare items, haha, fine, if you can give me something I don't have already, not only will I help you in this matter, I will even assist you in escaping this cloth, for you to return to this world with your own body."
"What do you want?" The girl became slightly moved and asked with a serious tone.
"It's very simple. Give me one of the nine Grand Heavenly Treasures then I will use everything in my power to help you escape the cloth and rebuild your body. Success is assured as long as I make up my mind."
"Of course, there are a few treasures I don't need among the nine. For example, the Myriad Thoughts Pot. Even if you can get it, I don't want it." He grinned at this point: "And yes, there are a few you can't get either like the Longevity Grass or the Void Gate. They can't be in your possession.
"If I have the nine treasures, why would I need to make a deal with you right now?" She said with exasperation.
"That's why there aren't that many things I can't get in this world. Even the top weapons in certain epochs are in my possession. Imperial weapons are just cabbages in my eyes."
The girl in yellow fell into a second silence. It looked like a wily old fox like Li Qiye was her nemesis.
"Of course, it's not like you don't have a chance." He smiled and said: "I can even help you come out in the future. When the time is right, rebuilding your body is fine too but I have a condition."
"What is it?" She eventually asked after a brief lull, understanding that a free lunch wasn't possible in this world. Li Qiye had all the initiatives.
"Very simple." He said slowly: "I only want one thing after releasing you from this sorry state, your loyalty and service for this generation!"
"That's impossible." She coldly refused.
He smiled in response: "Nothing is impossible in this world. I've seen many amazing women in the world. It doesn't matter how noble your origin might be, you are just a downtrodden phoenix right now, no, not even that."
"You!" She would be vomiting blood right now from anger if it was possible in her current state.
"I don't care whether you are willing or not." He continued: "This is ultimately up to you since it's no big loss to me, only a contributor at most. I can even groom emperors so there's no fear of not having new people."
He stopped and smirked: "It's not the same for you. I'm afraid there is no standing back up while being trapped in that cloth. Even if I was kind enough to release the cloth to the world, even if someone else were to pick it up, how many do you think can do the same as me, releasing and creating a new body for you?"
"Of course, you have plenty of time if you can withstand waiting till that day. Maybe it will be millions and millions of years later or a dozen epochs." He was very pleased with his teasing.
She contemplated for a moment before finally answering: "Fine, I accept but don't push it!" She still chose to compromise in the end.
Her origin was unbelievably noble but like he had said, she was nothing right now.
If she continued to refuse his offer, she would be trapped in the cloth forever. Even if she could wait until someone else finds the cloth, they wouldn't be as capable as him. After careful consideration, she came up with this decision despite her unwillingness to serve him. This was the only way to have hope in the future.
The two finally into an agreement. She said: "Now, you have to help me get something back."
"Don't worry, I'm a man of my word since we'll be a family then." He smiled and said.
"Who is family with you!" The girl expressed her annoyance once more.
After the conclusion of the arrangement, the two decided to leave. The matriarch told Li Qiye before the departure: "A second group of disciples from Soaring Immortal is entering the Grand Sea. They have sent many ancestors as well. I'm afraid even someone like Ancestor Long will be there too."
"Let them come then." Li Qiye leisurely said: "I actually want to see if those princes have actually escaped from the Immortal Confinement and just how strong they are." He was amused with the development.
"They can actually escape from there? I heard that it was virtually impossible to escape alive. Many geniuses from that sect have entered but the only one who successfully left was Immortal Emperor Can Long during his youth." She found this surprising.
"This prison is not a bad item at all. Immortal Emperor Fei expended great effort just to bring it to his sect. Those who can leave the prison are very powerful indeed." He smiled.
Of course, regardless of how powerful they might be, they were only his prey.
"However, Gu Zun isn't present. I used my divine intent to sweep through Heaven Suppression but he's not there." She said solemnly.
Despite her great power, she was very careful when dealing with someone as crafty as Gu Zun.
"He's just testing the water using Soaring Immortal as a pawn. He'll be hiding in the shadow to watch the fun." Li Qiye expected this.
"He'll never give up though and will eventually make a move. Given his personalities, it would be the regret of a lifetime to not personally kill me so he won't miss that chance." Li Qiye said with a smile.
"I'm just worried about his plans behind the scene." She said.
"Don't worry, doing that will only expose him. The guy is very careful and won't do anything so carelessly. At best, he'll only bait others into action. I know Gu Zun too well." Having said that, Li Qiye stared towards the horizon and chuckled: "I'm interested to see his killing move. Who knows how much work he has put in for revenge? If his ace move isn't something amazing, then it will be too disappointing. An eonic genius has to be better than that."
Aecommend: 5 Best Chinese Romance Books of 2018 So Far
All contents are copyrighted by their respective authors.


JHANSI JUNCTION JHS to MIRZAPUR MZP train timings, routes, stops, and complete info.
As of now, 2 trains run between from JHANSI JUNCTION (JHS) to MIRZAPUR (MZP).
The fastest train from JHANSI JUNCTION (JHS) to MIRZAPUR (MZP) is CHAMBAL EXPRESS (12176) that departs at 09:00 and arrives to at 18:15. It takes approximately 09:15 hours.


"The best place in NJ to learn how to ride a motorcycle and further develop your riding skills".
Enjoy the freedom and thrill of riding a motorcycle. Get your motorcycle license/endorsement in 18 hours by taking the Motorcycle Safety Foundation's BRC1.
The Basic RiderCourse (BRC1) is designed for those who want to learn how to ride a motorcycle and get their NJ motorcycle license/endorsement.
Are you riding around on just a motorcycle permit? Hesitant to take the DMV Road Test on your motorcycle? Get your motorcycle license/endorsement in 12 hours by taking the Motorcycle Safety Foundation's BRC2.
The Experience RiderCourse (BRC2) is designed for those who have a valid NJ motorcycle permit, have their own motorcycle (232cc or greater) that is registered and insured in NJ and want to get their NJ motorcycle license/endorsement.
Keep your riding skills sharp to help you avoid a crash by taking the Motorcycle Safety Foundation's ERC once a year.
Why do the military, police, firefighters and EMT's train so often? To be prepared for the unexpected. Constant training is one of the best ways to avoid a motorcycle crash. Motorcyclists should take the Experienced RiderCourse (BRC2) once a year to keep their riding skills sharp so they're prepared for the unexpected.
Need more practice before riding on the street?
The Additional Practice Basic RiderCourse (APBRC) is designed for those who completed the BRC1 and want some more practice before riding in the street, and for those who failed the BRC1 Skill Test and want a few more hours of practice before taking it again.
Never driven a clutch vehicle? Want some practice before taking the BRC1?
The Motorcycle Safety Foundation's Introductory Motorcycle Experience (IME) is designed for those who have never driven a clutch vehicle and for those who are thinking if riding a motorcycle is for them.
Crank up your turning skills to a higher level by learning how to trail brake and lean more by leaning less.
The Trail Braking Course (TBC) will show you how to navigate your turns smoother by trail braking and by leaning more by "kissing the mirror".
Subscribe to our newsletter so you can stay up-to-date with what we're doing, find out when we're offering the Advanced Courses (BRC2 & TBC) and get helpful motorcycle and riding tips. To sign up, click here. (Past issues of our newsletter are posted on our Facebook page).
If you would like to give one of our courses as a Birthday, Christmas, Graduation, Anniversary, Wedding, Father's Day or Valentine gift to someone, just click on the tab above for that course and scroll down to the Gift Certificate section on that page.
If you would like to help reduce motorcycle accidents in the State of NJ, click here.
Click here to see which Instructors are teaching a scheduled class.
We're looking for Motorcycle Safety Instructors. Click here for more details.
If you can't make the Orientation Session on 12/12/17, click the red Download button below to print or download a copy of the Instructor application. Then email it back to us.
To see what others have to say about us, click on each Course page at the top of this page and read their testimonials.
You can also read their reviews on our Facebook page and on Google Reviews.
We don't need to brag about our reputation. Our students do that for us.
Our new location is Montclair State University.
We moved our classroom location from the Big Boyz Toy Box on Shady St. in Paterson and our practice riding location from the KMart in Elmwood Park (KMart lost its lease and closed) to the prestigious Montclair State University. The location is easily accessible from several major highways; Rts. 3, 4, 7, 17, 19, 20, 21, 23, 46, 80, 287, GSP, NJ Turnpike.


text:
MEET DR. DAVID GELB
David A. Gelb, DDS completed his DDS and Certificate in Periodontics at Columbia University School of Dental and Oral Surgery in New York and his implant surgical training at the University of Toronto. He is a Diplomat of the American Academy of Periodontology, a Fellow Academy of Osseointegration, and a Fellow American and International college of Dentists. He is on staff at Hartford Hospital and has provided implant services in West Hartford for over twenty-five years.
Dr. Gelb has achieved global recognition as a leader in Implant dentistry having pioneered surgical procedures for finite esthetics in implant dentistry, immediate implant placement, and bone regeneration. He lectures nationally and internationally at major implant meetings and publishes extensively in journals worldwide on implant denistry. He developed the "Gelb Radiographic Depth Guage," a diagnostic surgical guide to heighten precise and optimum implant placement, and designed "The Implant Tracker," a comprehensive software program to manage the Implant practice.
Dr. Gelb continues to move forward with innovative implant surgical procedures including the unsurpassed "Teeth-In-One-Hour" and immediate loading. Dr. Gelb maintains a private practice limited to Periodontics and Implant Surgery in his state-of-the-art facility in West Hartford, Connecticut, where he and his dedicated staff serve patients from all over the world.
Dr. Gelb and his wife live in West Hartford. Dr. Gelb's wife Susanne Gelb, DDS is a Cosmetic Dentist in Hartford. They enjoy spending time with their four children and grandchildren. They are active in the community and are dedicated to their family, friends, neighbors and especially their patients.


Find the best promotion at the lowest prices with our Once Upon A Trunk promo codes and discounts.
Don't miss the season's lowest prices now at Once Upon A Trunk. Best Today: Free Shipping on All Orders Above Rs 1000. Click here to start shopping!


Subhra Priyadarshini is an award winning science and environment journalist currently running Nature Publishing Group's (NPG) India operation Nature India.
Be Happy & Smile Always.
I'm passionate about Physics and Indian Classical Music .I'm flutist too. I'm doing my Bachelors of Technology in Electronics and communication engineering in " The LNMIIT "-Jaipur, India. I also completed my Diploma in Flute - Carnatic CLassical -- with a Distinction.
COST is a proud partner of ESOF 2012 and invites all participants to join the COST Session S & T = Key 2 Knowledge - The added-value of collaborative networks on Friday 13 July from 12:15 to 14:45 - Wicklow Meeting Room 1 on level 2.
Dr. Tom Arbuckle is a Senior Member of the IEEE, Chartered Engineer, Member of the IET, Chartered Physicist, Member of the Institute of Physics, Chartered IT Professional, Member of the BCS, Chartered Scientist, Member of the ACM, Member of SIAM and a post-doctoral researcher at the University of Limerick. He earned an honours B.Sc. in chemical physics and a Ph.D. in electronics and electrical engineering from the University of Glasgow, UK.
Tom Martin is a certified management consultant and principal of Tom Martin & Associates.
Skinn på näsan, glimten i ögat. Ömmar för de små och tycker att resten borde sluta gnälla.


text:
To serve as a voice for science in society
The Brosnan Center is an affiliation of multi-disciplinary scientists and graduate students who work to make science matter in people's lives. Our mission is two fold:
1. To convene innovative minds to explore and find solutions to global challenges
Science is a uniquely human endeavor that has extraordinary potential to contribute to society. Our goal is to contribute to that potential. By strategic convening, engaging scientists with decision-makers we tackle current and emerging challenges.
We integrate across the sciences. Ecologists, neurobiologists, economists, geneticists, engineers, architects, physicists and many others are asking similar questions in order to understand the world, our place in the universe, and how to sustain our planet. However, many are unaware of this synchronicity, and the alternative approaches, knowledge, and possibilities it offers. The first mission of the Center is to integrate these disciplines around key questions.
2. To test and implement these innovative ideas at the local level to rebuild stable environments; we encourage science as a vehicle to engage people with their environment and the future.
We believe innovation should serve the needs of humanity. The second mission of the Brosnan Center focuses on community implementation and engaging people around science to work collectively on solutions that make a difference.
To implement our vision, members of the Brosnan Center conduct scientific research and engage in conservation initiatives. We then put that research to work by helping to craft law and policy frameworks based on science. By doing so, we advocate for effective, science-based solutions to today's pressing environmental problems.
Our goal is to reconnect people with the value, mystery, wonder and unique ability of science to make the world a better place.
Home Vision On Location The Work People Images and Video Blog Podcast Writings Connect Contact
© 2010 by Dr. Deborah Brosnan. All rights reserved.


text:
CSE's NOVEL COMPUTING (NCNC'14)
, Category: Conference
NATIONAL CONFERENCE ON NOVEL COMPUTING (NCNC'14)
The Department of COMPUTER SCIENCE ENGINEERING conducted a National level Conference titled "NATIONAL CONFERENCE ON NOVEL COMPUTING (NCNC'14)" which was held on 14/03/2014(Friday) at S.M.K Fomra Institute of Technology. Dr. P.Yogesh Associate professor - Department of IST ,Anna University was the chief guest for the occasion. The function started with the prayer song followed by lighting lamp by the chief guest Dr .P.Yogesh, HoD CSE – Mr.Robinson Joel , Convenor - Mr. S.P.Manikandan, Staff coordinator - Mr. R. Senthil Kumar and Student Coordinator S. Kalimuthu . The Convenor Mr. S.P. Manikandan welcomed the chief guest, HODs, Staff members and Students
The chief guest briefly discussed about the latest technology related to computer science and gave a speech regarding the importance of technology in day-to-day life. "The PROCEEDING OF NCNC'14" was released by the chief guest. More than 250 papers have been received for the conference and best of 119 papers have been published.
Prizes for top three papers were distributed at the valedictory Function In the presence of Chief Guest , Joint Correspondent – Mrs.Neha Fomra , Principal – Dr.Ushaa Eshwaran , HOD CSE- M.Robinson Joel and Convernor - Mr.S.P.Manikandan.
Mr.Robinson Joel ,HOD-CSE thanked the Management , Principal, HOD's, Staff members and participants from various colleges for their cordial presence and support.


The reasoning is a game of wits and presence of mind! Yes, it is true and it might seem as the greatest of the challenge after English Section's surprises but yet this one can easily be dealt with. You just need correct practice and hardwire your brain to quickly make decisions of what to attempt and what to leave. And for same we are providing you questions of Reasoning Question. To Practice more with these new pattern Reasoning Question for IBPS PO and Clerk Exam 2017.
There are total ten persons divided in two groups. In each group there is equal number of person. They sit in two parallel rows while they are in meeting. One group faces north while other group faces south in such a manner that each member of group one faces other member of group two. In group 1- there are five persons A, B, C, D and E and all of them facing towards north direction. In group2-there are five persons P, Q, R, S and T and all of them facing south direction. All of them like different colour like Pink, Red, Blue, Black, White, Green, Yellow, Violet, Brown and Orange but not necessarily in the same order. P sits third to right of Q. Immediate neighbor of Q faces the person who likes pink colour. There are gap of two persons between the one who likes pink and the one who likes red colour. There is only one person between R and S. Neither R nor T face the person who likes red colour . Immediate neighbor of P faces the person who like blue colour. E likes blue colour. There is only one person between E and the one who like Black colour. The one who likes white colour faces the one who likes the green colour. There are gap of two persons between the one who likes the white and the one who likes yellow colour. The one who likes the violet colour is not immediate nighbour of one who likes white colour. A likes red colour and sits third to left of D. B does not like black colour. R likes brown colour.
Q1.Who among the following sits at the corner?
Q2. Who sits third to right T?
(a)The one who likes orange colour.
(b)The one who likes yellow colour.
(c) The one who likes violet colour.
(d) The one who likes white colour.
Q3. S is related to A and R is related to E, in the same way T is related to?
Q4.Immediate neighbor of A faces which person?
Q5. Who among following likes yellow colour?
(b)The one who sits one of the corner.
(c) The one who sits third to left of R.
(d) The person who faces pink colour.
(e) The person who is immediate neighbor of one who like white colour.
Sol.The one who likes orange colour.
Sol.The one who sits one of the corner.
Directions (6-10): Each of the questions below consists of a question and two statements numbered I and II given below it. You have to decide whether the data provided in the statements are sufficient to answer the question.
Q6. On which day in September was definitely Shobha's mother's birthday?
I. Shobha correctly remembers that her mother's birthday is before eighteenth but after twelfth September.
II. Shobha's sister correctly remembers that her mother's birthday is after fifteenth but before nineteenth July.
Q7. How is 'too' written in a code language?
I. 'go too the tree' is written as 'sa na pa ta' in that code language.
II. 'tree is too home' is written as 'ja pa da sa' in that code language.
Q8. Among A, B, C, D and E, each having scored different marks in an exam, who has scored the lowest marks?
I. D has scored more marks than only three of them.
II. A has scored more marks than only E.
Q9. What is the position of P with respect to Q(Counted from left of Q) in a round table seating arrangement if all of them are facing towards the center of table?
I. Seven persons P, Q, R, S, T, U and V sat around a round table where P sat between U and V, S sat adjacent to V and R did not sit adjacent to S.
II. T sat on the immediate right of U.
Q10. How is T related to W?
I. P is brother of M and fatherof T. M is the son of W.
II. M is father of S. V is grandmother of S.
Sol. From statement II- E scored the lowest mark.
Q11. Statements: Directions (11-15): In each of the questions below are given four statements followed by four conclusions numbered I, II, III & IV. You have to take the given statements to be true even if they seem to be at variance with commonly known facts. Read all the conclusions and then decide which of the given conclusions logically follows from the given statements disregarding commonly known facts.
I. Some dresses are cars.
II. Some nets are books.
III. Some shops are books.
IV. Some dresses are books.
I. Some trains are cars.
II. Some jungles are cars.
III. Some trains are desks.
IV. Some jungles are kites.
I. Some roads are fruits.
II. Some lanes are clips.
III. Some fruits are mobile.
IV. Some roads are clips.
I. Some buses are jeans.
II. Some wheels are shirts.
III. Some wheels are pens.
IV. Some buses are shirts.
No hammer is a ring.
I. Some chairs are laptops.
II. Some chairs are rings.
III. No chairs is a laptops.
IV. Some rings are laptops.
i have doubt in question no.9, there are two possible cases using both the statements and hence the answer should be (d) the data given in both statement I and II together are not sufficient to answer the question.


text:
SILVER CROW BOOKS
Nikki Copleston
Nikki Copleston is a crime writer who was the granddaughter of a policeman and feels she has an affinity with the force. She is conscientious about her work - she writes every day and when not in front of her computer, her mind revolves around her plot. But she has found that she has also to be active in marketing her book, even if raising her literary profile means taking a few risks. 'Natural modesty is not much use to a writer,' she says. So she now has a blog, a Facebook page, and has developed a crime-writers' workshop for beginners.
Her advice to new writers is to Read, Read, Read! 'You learn from good writers, become analytical. You also learn not to be too precious about your own words and characters. If they don't serve the plot, get rid of them!'
Nikki is a trustee of Frome Writers' Collective, a member of the Frome Small Publishers' Fair group and a member of West of England Authors group.
Read her blog at at nikkicopleston.com.
Brenda Bannister
Wendy Worley
Brenda Bannister is a talented and successful storywriter. She has published seven stories in Woman's Weekly, came second in the 2012 Wells Festival Short Story Competition, has had two poems published and writes a regular column for the Western Daily Press.
Her first novel explores the lives of two disparate teenage girls; one, the Edwardian daughter of a tobacco merchant, the other the youngest daughter of a Bangladeshi family. Their connection is the house they both live in - a hundred years apart. Both a ghost story and a social commentary, it describes the effect of family influences on them both. Brenda's inspiration came from the old houses in the area in London's East End, where she used to work, and the changes they had witnessed.
She believes in writers helping writers and she put this into practice by becoming a founder member and trustee of the Frome Writers Collective.
Facebook link: https://www.facebook.com/thetissueveil/?fref=ts
Wendy Worley lives on the Mendip Hills near Frome. As a child, Wendy always had her nose in a book, and spent many hours browsing in the local library. Her working career began as a scientist, followed by a brief spell in the Met Office and a post in building research.
It was when Wendy moved on to become a school science technician, however, that her literary interests re-emerged and she volunteered to run the school library. A few years and an Open University degree later, she joined Sidcot School as a full time librarian.
There, she immersed herself in children's literature and in organising author events where the contact with a host of talented authors inspired her to write herself.
Being an author is now her full-time occupation and she is currently working on her second manuscript, a fictional tale set in the Lake District. Wendy continues to be an enthusiastic reader and regularly reviews books for the School Library Association.
Dizzy Greenfield


text:
Q: Nested Formarrays in Angular6 I'm trying to insert formarrays in a formarray to work. But I can't see to do it right. the idea is to have the below to work in a form:
Item[0]:
   Sku: "string",
   Received: "string",
   Quantity: "string",
   Tracking[0]: "string",
   Tracking[1]: "string"
Item[1]:
   Sku: "string",
   Received: "string",
   Quantity: "string",
   Tracking[0]: "string"
Each item is supposed to have a nested array called "tracking." I'd like to add a button next to each item array to add a tracking.
Here's what I have so far:
create-return.component.ts
import { Component, OnInit } from '@angular/core';
import { MatFormField, MatSelect, MatToolbar } from '@angular/material';

import {
  FormControl,
  FormGroup,
  FormBuilder,
  FormArray,
  Validators
} from '@angular/forms';
import { ReturnsService } from '../../returns.service';

@Component({
  selector: 'app-create-return',
  templateUrl: './create-return.component.html',
  styleUrls: ['./create-return.component.css']
})
export class CreateReturnComponent implements OnInit {
  inputData: FormGroup;

  constructor(private returns: ReturnsService, private fb: FormBuilder) {
    // this.inputData = new FormGroup({
    //   items: new FormGroup({
    //     sku: new FormControl(),
    //     quantity: new FormControl(),
    //     received: new FormControl()
    //   }),
    //   orderId: new FormControl(),
    //   isPrime: new FormControl(),
    //   note: new FormControl(),
    //   reason: new FormControl()
    // });
  }

  ngOnInit() {
    this.inputData = this.fb.group({
      items: this.fb.array([], Validators.required),
      // trackings: this.fb.array([], Validators.required),
      orderId: ['', Validators.required],
      isPrime: ['', Validators.required],
      // note: '',
      reason: ''
    });

    this.addItemToForm();
    this.addTrackingsToForm();
    // console.log(this.inputData);
    console.log(this.itemsForm.controls[0]);
  }

  get itemsForm() {
    return this.inputData.get('items') as FormArray;
  }

  get trackingsForm() {
    let track = this.itemsForm as FormArray;
    // return this.itemsForm.get('sku') as FormArray;
    return track;
  }

  addItemToForm() {
    const items = this.fb.group({
      sku: ['', Validators.required],
      quantity: ['', Validators.required],
      received: ['', Validators.required],
      trackings: this.fb.array([])
    });

    this.itemsForm.push(items);
  }

  addTrackingsToForm() {
    const tracking = this.fb.group({
      trackings: ['', Validators.required]
    });

    this.trackingsForm.controls[0]['controls']['trackings'].push(tracking);
  }

  deleteItemFromForm(i) {
    this.itemsForm.removeAt(i);
  }

  deleteTrackingFromForm(i) {
    this.trackingsForm.removeAt(i);
  }

  submitData() {
    console.log(this.inputData.value);
    // this.returns.createReturn(this.inputData.value).subscribe(data => {
    //   this.returns.openSnackBar('Return Created!', '');
    //   this.inputData.reset();
    // });
  }
}

create-return.component.html

<form [formGroup]="inputData" class="center-width-separator" style="margin-top: 2%;">
  <mat-card>
    <mat-toolbar class="center-width-separator mat-header-create">
      Create Return
    </mat-toolbar>
    <mat-card-title>Order</mat-card-title>
    <mat-form-field class="input-separator">
      <input matInput placeholder="Order ID" formControlName="orderId">
    </mat-form-field>
    <mat-form-field>
      <mat-select formControlName="isPrime" placeholder="Prime?">
        <mat-option value="true">Yes</mat-option>
        <mat-option value="false">No</mat-option>
      </mat-select>
    </mat-form-field>
    <button mat-stroked-button (click)="addItemToForm()" style="margin: 0 5px;">Add Item</button>

      <mat-card-title style="padding-top: 10px;">Items</mat-card-title>

        <mat-form-field class="input-separator">
          <input matInput placeholder="Sku" formControlName="sku">
        </mat-form-field>

        <mat-form-field class="input-separator">
          <input matInput placeholder="Quantity" formControlName="quantity">
        </mat-form-field>

        <mat-form-field class="input-separator">
          <input matInput placeholder="Received" formControlName="received">
        </mat-form-field>
        <button mat-stroked-button (click)="addItemToForm()" style="margin: 0 5px;">Add Item</button>
        <button mat-raised-button color="warn" (click)="deleteItemFromForm(i)" style="margin: 0 2%;">Delete Item</button>

          <mat-card-title style="padding-top: 10px;">Trackings</mat-card-title>

            <mat-form-field class="input-separator">
              <input matInput placeholder="Tracking Number" formControlName="trackings">
            </mat-form-field>

    <mat-divider></mat-divider>

    <button mat-raised-button color="primary" [disabled]="inputData.invalid" (click)="submitData()">Submit</button>
  </mat-card>

</form>

Any help will be appreciated. Thank you
edit: The problem:
Whenever I add an Item group, a tracking field gets added to the field. What I need is each Items field to have each own tracking field. Sometimes they'll have zero, some other times 3 or more.

redpajama_set_name: RedPajamaStackExchange


text:
6 Health Care Themes We'll Be Watching During HIMSS19
Published on February 7, 2019
Estimated read time: 8 minutes
The HIMSS19 Global Conference & Exhibition is one of the biggest events in health care, bringing together more than 45,000 industry professionals and thought leaders from around the world for a week of education and networking. Here are six health care topics that will take center stage at the conference:
1. Usability and the physician burnout problem
Physician burnout is not a new problem – A 2019 Medscape study found that 44 percent of U.S. physicians suffer from burnout, making this one of the most pressing issues we're experiencing in health care today. As physicians suffer, turnover rates surge, the quality of patient care declines and medical errors become increasingly common.
The roots of physician burnout are difficult to pin down, but Dr. Chris Lewis, a physician executive at Cerner, breaks the causes into four main categories: autonomy, communication, physician engagement and physician expectations. As burnout rates grow, health care organizations need to prioritize mental health resources while also providing flexible EHR training to improve physician satisfaction.
Effectively confronting physician burnout begins with creating workflows that are functional, reliable, usable, convenient, pleasurable and meaningful. Fixing this industrywide challenge will require collaboration and cooperation among providers and vendors alike.
At HIMSS19, expect health information and technology professionals to engage with clinicians on how to better accommodate their care delivery workflows for a more personalized and intuitive experience.
SUGGESTED SESSION
Panel Presentation: Moral Distress with Burden of Documentation: Call to Action
Susan G. McBride, PhD, RN-BC, CPHIMS, FAAN, nursing informaticist, Texas Tech University Health Sciences Center
Date: Thursday, February 14, 11:30 a.m. – 12:30 p.m. EST
Room: W303A
2. Customer relationship management and engaging consumers in health care
Consumerism — the notion that people make purchasing decisions based on information about health care cost and quality —is here to stay. As people pay more out of their own pockets for health care, they'll continue to look for ways to manage those expenses. More and more, consumers are demanding seamless interactions across health care organizations, including price transparency for services and prescriptions.
The growth of new technologies, such as virtual reality, augmented reality, artificial intelligence, and customer relationship management (CRM) systems is shifting care delivery to a more personalized, convenient and effective experience. Consumers are encouraged to collaborate with their physicians and be engaged in their own health and care. The industry is being redefined as care encounters move from a physical space to a digital ecosystem. These changes empower providers to better understand and serve consumer and patient needs.
At HIMSS19, Cerner and Salesforce will present health care professionals with a clinically-informed, enterprisewide customer relationship management system that can help organizations know, engage and manage the health of their populations.
Panel Presentation: Salesforce Customer Success Theatre Presentation
Emily Allen, healthcare strategic partnerships, Salesforce
Peter Yates, director Cerner Health Ventures, Cerner
Date: Tuesday, February 12, Noon-12:30 p.m. EST
Room: Salesforce booth #3311
3. Commitment to innovation through open code and HL7 v4
Since its creation in late 2011 and subsequent release in 2014, Health Level Seven International's (HL7) Fast Healthcare Interoperability Resources® (FHIR) standard has led the way in providing developers and software engineers with the tools to integrate their applications into health care ecosystems, further empowering clinical communities across the globe.
HL7 recently reached a key milestone when it released its FHIR Release 4 (or R4) earlier this year. R4 represents HL7's first normative release of the framework, which is expected to improve access to complete patient records and support a broader suite of applications for the foreseeable future.
As methods of health care delivery evolve, patient-centered health care is increasingly depending on the ability to aggregate health data across provider networks. In the ongoing shift to value-based systems, care providers are seeking innovative technologies and applications to support everchanging care models. Open code platforms, such as the Cerner Open Developer Experience (code), use these standards to encourage innovation in care delivery by allowing the integration of apps into entire health ecosystems.
At HIMSS19, look for meaningful dialogue and collaborative efforts between health care providers, IT vendors and third-party app developers. While R4 is a momentous step in the right direction for flexibility and efficiency in interoperability, the momentum will not stop there – HL7 FHIR Release 5 is expected to publish in the third quarter of 2020.
Panel Presentation: Dignity Health Boosts Medication Adherence with SMART on FHIR
Sarah Toy-Ding, enterprise clinical informaticist, Dignity Health
Tiffany Shields, enterprise clinical informaticist, Dignity Health
Date: Monday, February 11, from 3-3:30 p.m. EST
Room: Rosen Centre Grand Ballroom C
4. Modernizing government health care
Public sector health agencies on the federal, state and local levels rely on clinical, operational and financial solutions that are provider- research- and policy-based. Streamlining health system operations and reducing costs while maintaining high-quality services is a must for these organizations.
As leaders work together to improve veteran and military health care through modernizing the Department of Veteran Affairs' (VA) EHR, active service members and veterans can look forward to seamless care in a single longitudinal health record. Other top priorities in the U.S. health care landscape are behavioral health, the opioid crisis and chronic diseases. Improving outcomes in these areas requires technology that can optimize workflows and aggregate health information records across the continuum.
HIMSS19 is an opportunity for health care technology experts to connect with government providers on intelligent, secure solutions that support their unique populations.
Panel Presentation: EHR: The Road to Transforming Military and Veteran Healthcare
John Windom, executive director for the VA Office of Electronic Health Record Modernization
Stacy Cummings, program executive officer for Defense Healthcare Management Systems
Date: Wednesday, February 13, 10-11 a.m. EST
Room: W304E
5. CommonWell-Carequality Connection promoting the next generation of interoperability
Interoperability and the capacity to share and exchange vital information between health care providers is a key and fundamental element of successful care coordination. It's something the industry has desired and needed for many years.
Luckily, this shared mission is the motivation behind much of the collaboration and innovation that we are seeing in health care today. For instance, in August 2018, CommonWell Health Alliance Executive Director Jitin Asnaani provided an update on the CommonWell-Carequality Connection, sharing the following details:
CommonWell has met all Carequality requirements to move into production.
Greenway Health and Cerner have a handful of initial providers live on the connection, allowing us to validate and benchmark the CommonWell-Carequality Connection.
The initial rollout continues to go well. In the first two months, CommonWell-enabled providers to bilaterally exchange more than 78,000 documents with Carequality-enabled providers.
At HIMSS19, Asnaani, along with Dave Cassel, vice president of Carequality, will co-headline "Making True Nationwide Interoperability a Reality," a session that will highlight the CommonWell-Carequality Connection. Through collaborative efforts, this partnership will allow care venues to exchange patient data from any organization, propelling patient care forward. Look for both leaders to share their experiences of working through this initiative at the HIMSS19 Interoperability Showcase.
Panel Presentation: Making True Nationwide Interoperability A Reality
Moderator: Dr. David McCallie, senior vice president, medical informatics, Cerner
Jitin Asnaani, executive director, CommonWell
Dave Cassel, director, Carequality
Dr. Mike Donnenwerth, chief of surgical & specialty care services, Winona Health
Kathy Callan, executive director, information systems, Gundersen Health System
Date: Wednesday, February 13, 9:30 – 10:30 a.m. EST
Room: Hall F 9100| Interoperability Showcase | Theater
6. The importance of a global perspective in health care
The systems and structures through which health and care are delivered to populations vary across the globe, however, the emphasis on delivering high quality care across venues is universal. A global outlook provides opportunities for collaboration and sharing of best practices between countries and informs the development of new solutions to deliver smarter care, better outcomes and healthier populations.
The boundaries of clinical acute, primary, community and social care are increasingly being broken down in global markets. Seamless interoperability between disparate systems and the aggregation, normalization of data provides insights that serve the quadruple aim of advancing care outcomes while lowering the cost of care and improving the experiences of both consumers and care providers.
At HIMSS19, health care leaders from more than 90 countries will join forces to connect across geographical borders and build relationships that drive smarter care and better outcomes.
Panel Presentation: EU/US Collaborations to Ensure a Capable eHealth Workforce
Marisa Wilson, BS, CPHIMS, DNSc, FAAN, MHS, RN-BC, associate professor, University of Alabama-Birmingham
Paula M. Procter, RN, PGCE, MSc, SFHEA, FBCS, CITP, FIMIAN, reader in informatics and telematics in nursing, Sheffield Hallam University
Date: Thursday, February 14, 4-5 p.m. EST
Cerner is exhibiting at HIMSS, February 11-15, 2019 in Orlando, Florida. Visit us in booth 2941 to explore our suite of solutions and services and dive into discussions on the latest health care topics with leading experts. Learn more here.


text:
Home Entertainment Akuapem Poloo Makes Another Appeal For Her 90-day jail term
Akuapem Poloo Makes Another Appeal For Her 90-day jail term
Ghanaian actress and social media influencer, Rosemond Brown who is known as Akuapem Poloo has filed a notice of appeal at the Court of Appeal through her lawyers.
Akuapem Poloo has gone through a lot this year, she was arrested and put into cells for posting a photo of herself with his only son. Now the picture wasn't the problem but posing n@ked in front of the child brought all these issues.
She was taken to court where the judge sentenced her to prison for 90 days, Akuapem Poloo and her lawyers filed an appeal to challenge the judgement but their appeal was thrown out by the court and she is now forced to serve her 90 days jail terms.
Now Akuapem Poloo is once again challenging the dismissal of her appeal by the High Court with regard to her 90–day jail term for posting a nude picture of herself and her son on social media.
Read also: Just In: Akuapem Poloo To Serve 90 – Day Jail Term As Court Dismisses Appeal
Akuapem Poloo's lead lawyer, Andrew Kudzo Vortia has filed a long notice of appeal on Monday, December 6, 2021, to the court.
The notice said: "Please take note that the convict/appellant/appellant herein, being aggrieved by the judgement of the High Court Criminal Division (1)Accra, Her Ladyship Ruby Aryeetey dated 1 December 2021 dismissing the appellant appeal against the conviction and sentenced to 90 days imprisonment imposed on the appellant on each count to run concurrently by Her Honour Mrs Christiana Cann dated April 16, 2021, hereby appeals to the court of appeal on the grounds set out below and for the release stated hereunder".
"That the learned judge erred in failing to appreciate that as a young first offender and a single parent, a noncustodial sentence of a fine instead of a custodial sentence of 90days imposed on the appellant by the trial court is appropriate in this case. That the custodial sentence of 90 days imposed on the appellant be set aside and in lieu, be substituted with a non-custodial sentence or a fine," it stated.
Akuapem Poloo's lawyers have also made an application for bail for her pending the determination of the case.
Remember that the Accra High Court on Wednesday, December 1, 2021, ordered Akuapem Poloo to go back and complete her 90-day jail term at the Nsawam Medium Security Prison. The order was made by the court after her appeal to overturn her 90 days jail terms were dismissed.
Previous articleShatta Wale, Medikal court cases adjourned to allow them to travel outside for concerts
Next articleDangote Revealed Why Africa Needs 20 Of Akufo-Addo Type To Develop
Ten Female Filmmakers Doing Great In The Movie Industry (photos)
Burna Boy Apologizes To Everyone As He Bow Out Of Fight With Shatta Wale
Black Sherif Took Over Sarkodie's #Rapperholic21 With Mega Performance


text:
package com.uresume.jordan.util;

public class Strings {

	public static String APPLICATION_NAME = "uCurriculumVitae";
	public static String VERSION = "v1.0";

	public static String LORUM_IPSUM = "Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer dolor metus, interdum at scelerisque in, porta at lacus. Maecenas dapibus luctus cursus. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec ultricies massa et erat luctus hendrerit. Curabitur non consequat enim. Vestibulum bibendum mattis dignissim. Proin id sapien quis libero interdum porttitor.";

}